Study finds relationship between higher vitamin D, lower risk of benign uterine tumors
RESEARCH TRIANGLE PARK, N.C. — Vitamin D significantly reduces women’s risks of developing uterine fibroids, according to a new study.
The study, conducted by the National Institute of Environmental Health Sciences, part of the National Institutes of Health, found that sufficient amounts of vitamin D reduced the risk of uterine fibroids by 32%. Fibroids, also known as uterine leiomyomata, are benign tumors of the uterus that often result in pain and bleeding in premenopausal women and are a leading cause of hysterectomies. Vitamin D can come from food and supplements, but the body also produces it naturally when the skin is exposed to sun.
"It would be wonderful if something as simple and inexpensive as getting some natural sunshine on their skin each day could help women reduce their chance of getting fibroids," NIEHS researcher and lead study author Donna Baird said.
The study included 1,036 women ages 35 years to 49 years living in the Washington metropolitan area between 1996 and 1999. Researchers at the NIEHS, George Washington University and the Medical University of South Carolina screened participants for fibroids using ultrasound and measured vitamin D in their bloodstreams. Those with more than 20 ng of vitamin D per mL of blood were categorized as sufficient, but some experts think greater amounts are needed for good health.
Similasan announces new hires to director team
HIGHLANDS RANCH, Colo. — Similasan North America today annouced the addition of two new team members to join the company at the director level.
Kim Stark has been named the new director of regulatory affairs and quality assurance. Stark comes to the company with over 10 of years of experience in quality assurance and regulation. For the past 5 years Stark was the director, Global Quality and Regulatory Affairs for Nspire Health Inc. Stark has a degree in Chemistry from the University of Colorado as well as a degree in Criminology from Regis University. Stark started last week, Monday, April 8.
Dora Newlin has joined the marketing team as the new director of marketing. She began last Tuesday, April 9. Newlin comes to Similasan by way of Procter & Gamble, where she worked on Cover Girl, and Orange Glo natural cleaning products. Newlin had been working for Launch Pad, LLC for the past several years. Newlin graduated from the University of Colorado, in Journalism and Mass Communications. She also has over 10 years in the industry with proven results managing and leading teams.
Similasan North America is headquartered south of Denver, Colorado. Similasan makes homeopathic products that offer gentle remedies to provide symptomatic relief from ailments of the eyes, ears, nose, nerves, cough & cold, and kids.
NAD recommends B+L make changes to advertorial claims
NEW YORK — Earlier this week the National Advertising Division recommended that Bausch + Lomb modify or discontinue certain claims made in an advertorial context that refer to Alcon Laboratories’ Opti-Free RepleniSH contact lens solution.
The advertorial, challenged by Alcon, alerted eye care practitioners to an increase in reports of infiltrative keratitis, a condition that can affect the vision and comfort of contact lens wearers. Titled “Infiltrative Keratitis and Gram-Negative Bacterial Resistance to PQ-Aldox Lens Care Products,” the advertorial suggested “contact lens associated infiltrative keratitis has been reported at higher rates in particular with polyquaternium (PQ)-Aldox (myristamidopropyl dimethylamine) based multi-purpose solutions.”
In this case, NAD determined that the challenged advertorial conveyed the messages that consumers who wear silicone hydrogel lenses and use Opti-Free RepleniSH are substantially more likely to experience, or are at a greater risk for, keratitis than other contact lens solutions; and that eye care practitioners should switch their patients to the advertiser’s Biotrue solution which has been shown to reduce their patients’ risk for keratitis.
NAD determined that the advertiser’s evidence did not support any of these messages. NAD recommended that B+L modify its advertorial.
B+L, in its advertiser’s statement, said that while the company respectfully disagrees with NAD’s findings concerning the net impressions of the advertorial, it “appreciates NAD’s recommendations on how to avoid any future confusion about the intended message. Bausch + Lomb will seek ways in which to incorporate this helpful guidance in any future advertising or promotional communications about this emerging field of study.”